NCT07414602

A Phase I Study of Single Subcutaneous Dose of SHR-1894 in Healthy Subjects

A Randomized, Double-blind, Placebo-controlled Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Subcutaneous Doses of SHR-1894 in Healthy Subjects

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 40 (estimated)
• Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 45 Years
• Healthy volunteers: Accepted

Summary

The Phase I clinical study aims to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of SHR-1894 in healthy subjects.

Conditions

• Dermatitis

Interventions

Type	Name	Description
DRUG	SHR-1894 Injection	SHR-1894 injection.
DRUG	SHR-1894 Injection Placebo	SHR-1894 injection placebo.

Timeline

• Start date: 2026-03-16
• Primary completion: 2026-10-01
• Completion: 2026-12-01
• First posted: 2026-02-17
• Last updated: 2026-03-18

Locations

1 site across 1 country: China